Our sister publication Consumer Reports Health has posted a new video in their AdWatch series, which examines direct-to-consumer pharmaceutical advertising. This time they’re examining some “stealth” advertising for the quit-smoking drug Chantix.
NY Magazine has published a interesting personal account from a patient who was taking the smoking-cessation drug Chantix. The FDA has reported 37 suicides and more than 400 reports of suicidal behavior in connection with Chantix, a pleasure blocking drug that sits in the nicotine receptors and prevents the smoker from properly experiencing their nicotine high. The FDA recently issued a patient advisory about the drug, requesting that patients carefully monitor their moods. The possible side-effects of Chantix now include “anxiety, nervousness, tension, depressed mood, unusual behaviors and thinking about or attempting suicide.”